Rivoglitazone (INN) is a thiazolidinedione derivative undergoing research for use in the treatment of type 2 diabetes.

[1][2] It is being developed by Daiichi Sankyo.

This drug article relating to the gastrointestinal system is a stub.

You can help Wikipedia by expanding it.